Base de dados : MEDLINE
Pesquisa : C06.405.205.865 [Categoria DeCS]
Referências encontradas : 2004 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 201 ir para página                         

  1 / 2004 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28407649
[Au] Autor:Haber R; Maatouk I; de Barbeyrac B; Bagot M; Janier M; Fouéré S
[Ad] Endereço:From the *Dermatologie et Vénéréologie, Hopital Saint Louis, Universités Bobigny, Paris, France; †Dermatologie et Vénéréologie, Hopital Hammoud, Beyrouth, Liban; ‡Centre National de Référence des Chlamydiae et des Mycoplasma, Université de Bordeaux, Bordeaux ; and §Dermatologie et Vénéréologie, Hopital Saint Louis, Paris, France.
[Ti] Título:Lymphogranuloma Venereum-Serovar L2b Presenting With Painful Genital Ulceration: An Emerging Clinical Presentation?
[So] Source:Sex Transm Dis;44(5):310-312, 2017 May.
[Is] ISSN:1537-4521
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:These 5 cases of atypical inflammatory lymphogranula venereum (LGV) serovar L2b presenting initially with edema and persistent painful ulceration illustrate that clinical manifestations of LGV in the current outbreak in men who have sex with men reflect the influence of both the serovars virulence and the host immune system and are not confined to proctitis. L2b serovar could have a particular high virulence profile, and the need for awareness of LGV as a cause of genital ulceration is crucial.
[Mh] Termos MeSH primário: Chlamydia trachomatis/imunologia
Homossexualidade Masculina/estatística & dados numéricos
Linfogranuloma Venéreo/microbiologia
Úlcera/microbiologia
[Mh] Termos MeSH secundário: Adulto
Chlamydia trachomatis/patogenicidade
Edema/diagnóstico
Edema/imunologia
Edema/microbiologia
Genitália Masculina/microbiologia
Genitália Masculina/patologia
Seres Humanos
Sistema Imunitário
Linfogranuloma Venéreo/diagnóstico
Linfogranuloma Venéreo/patologia
Masculino
Meia-Idade
Proctite/diagnóstico
Proctite/microbiologia
Proctite/patologia
Sorogrupo
Úlcera/diagnóstico
Úlcera/patologia
Virulência
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170809
[Lr] Data última revisão:
170809
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170414
[St] Status:MEDLINE
[do] DOI:10.1097/OLQ.0000000000000597


  2 / 2004 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28367587
[Au] Autor:Markos P; Bilic B; Ivekovic H; Rustemovic N
[Ad] Endereço:Department of Gastroenterology and Hepatology, Endoscopy Unit, University Hospital Centre Zagreb, Kispaticeva 12, 10000, Zagreb, Croatia. pave.markos@gmail.com.
[Ti] Título:Radiofrequency ablation for gastric antral vascular ectasia and radiation proctitis.
[So] Source:Indian J Gastroenterol;36(2):145-148, 2017 Mar.
[Is] ISSN:0975-0711
[Cp] País de publicação:India
[La] Idioma:eng
[Ab] Resumo:Gastric antral vascular ectasia (GAVE) and chronic radiation proctitis (CRP) are well-known causes of repeated gastrointestinal bleeding and iron deficiency anemia. Argon plasma coagulation (APC) is the most common endoscopic therapy used, but some patients need multiple APC sessions. Radiofrequency ablation (RFA) is recently used in GAVE and CRP treatment with promising results. In this case series, we analyzed data for 15 patients with GAVE and 5 patients with CRP that had multiple prior APC treatment. They were treated with RFA HALO 90 catheter (HALO90 Ablation Catheter System; Covidien, GI Solutions, Sunnyvale, CA) in our tertiary referral center. A total of 20 patients received 32 RFA procedures (8 in the CRP group and 24 in the GAVE group). The median number of the procedures was 2 (range 1-4). The hemoglobin levels in the GAVE group were 83 g/L pre-RFA and 98 g/L post-RFA and in the CRP group, 86 g/L pre-RFA and 103 g/L post-RFA. A total of 16/20 patients (80%) were transfusion-free after the completion of RFA treatment. Technical success of the treatment was 95% (19/20 patients). RFA can be safely and successfully used in APC refractory GAVE and CRP patients.
[Mh] Termos MeSH primário: Ablação por Cateter/métodos
Ectasia Vascular Gástrica Antral/cirurgia
Proctite/etiologia
Proctite/cirurgia
Radioterapia/efeitos adversos
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Anemia Ferropriva/etiologia
Anemia Ferropriva/prevenção & controle
Doença Crônica
Feminino
Hemorragia Gastrointestinal/etiologia
Hemorragia Gastrointestinal/prevenção & controle
Seres Humanos
Masculino
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171110
[Lr] Data última revisão:
171110
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170404
[St] Status:MEDLINE
[do] DOI:10.1007/s12664-017-0748-2


  3 / 2004 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28366579
[Au] Autor:Rijkmans EC; Cats A; Nout RA; van den Bongard DHJG; Ketelaars M; Buijsen J; Rozema T; Franssen JH; Velema LA; van Triest B; Marijnen CAM
[Ad] Endereço:Department of Radiotherapy, Leiden University Medical Center, Leiden, The Netherlands. Electronic address: e.c.rijkmans@lumc.nl.
[Ti] Título:Endorectal Brachytherapy Boost After External Beam Radiation Therapy in Elderly or Medically Inoperable Patients With Rectal Cancer: Primary Outcomes of the Phase 1 HERBERT Study.
[So] Source:Int J Radiat Oncol Biol Phys;98(4):908-917, 2017 Jul 15.
[Is] ISSN:1879-355X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To evaluate the toxicity and efficacy of the combination of external beam radiation therapy (EBRT) followed by high-dose-rate endorectal brachytherapy (HDREBT) boost in elderly and medically inoperable patients with rectal cancer. METHODS AND MATERIALS: A phase 1 dose-escalation study was performed. Treatment consisted of EBRT (13 × 3 Gy) followed by 3 weekly brachytherapy applications 6 weeks later. The HDREBT dose started at 5 Gy per fraction, increasing with 1 Gy per fraction if dose-limiting toxicity (DLT, defined as grade ≥3 proctitis <6 weeks after HDREBT) occurred in ≤2 patients per dose level. The primary endpoint was the maximum tolerated dose, defined as 1 dose level below the dose at which 3 patients experienced DLT. Secondary endpoints were toxicity, clinical tumor response, freedom from local progression, and local progression-free and overall survival (L-PFS and OS). RESULTS: Thirty-eight patients with a median age of 83 years were included in the study. Thirty-two were evaluable for DLT and late toxicity and 33 for response evaluation. Maximum delivered dose was 8 Gy per fraction, resulting in a recommended dose of 7 Gy per fraction. Response occurred in 29 of 33 patients (87.9%), with 60.6% complete response (CR). The L-PFS and OS rates were 42% and 63%, respectively, at 2 years. Patients with CR showed a significantly improved L-PFS (60% at 2 years, P=.006) and a trend in improved OS (80% at 2 years, P=.11). Severe late toxicity occurred in 10 of 32 patients. CONCLUSION: We found that HDREBT after EBRT results in a high overall response rate, with improved L-PFS for patients with a CR. The high observed rate of severe late toxicity requires further evaluation of the risks and benefits of an HDREBT boost.
[Mh] Termos MeSH primário: Adenocarcinoma/radioterapia
Braquiterapia/métodos
Idoso Fragilizado
Neoplasias Retais/radioterapia
[Mh] Termos MeSH secundário: Adenocarcinoma/mortalidade
Adenocarcinoma/patologia
Idoso
Idoso de 80 Anos ou mais
Intervalo Livre de Doença
Fracionamento de Dose
Feminino
Seres Humanos
Masculino
Dose Máxima Tolerável
Meia-Idade
Proctite/etiologia
Neoplasias Retais/mortalidade
Neoplasias Retais/patologia
Resultado do Tratamento
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE I; JOURNAL ARTICLE
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170728
[Lr] Data última revisão:
170728
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170404
[St] Status:MEDLINE


  4 / 2004 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28183394
[Au] Autor:Petrovay F; Balla E; Erdosi T
[Ad] Endereço:Department of Bacteriology II., National Centre for Epidemiology, Budapest, Hungary.
[Ti] Título:Emergence of the lymphogranuloma venereum L2c genovariant, Hungary, 2012 to 2016.
[So] Source:Euro Surveill;22(5), 2017 Feb 02.
[Is] ISSN:1560-7917
[Cp] País de publicação:Sweden
[La] Idioma:eng
[Ab] Resumo:In eastern Europe, few countries have so far reported laboratory-confirmed cases of lymphogranuloma venereum (LGV). Here we describe 22 LGV cases in men who have sex with men (MSM) detected in Hungary from November 2012 to July 2016. Sequence analyses show that 16 of these 22 cases were affected by the L2c genovariant, with from 2012 to 2014, one LGV L2c case detected per year, followed by seven cases in 2015 and six up to July 2016. Of the 16 total L2c LGV cases, 10 had severe haemorrhagic proctitis. These findings are concerning as cases with this new genovariant among MSM have not been frequently reported in Europe to date. More research is needed to assess the spread of the L2c genovariant and its potential association with virulence and severe clinical manifestation.
[Mh] Termos MeSH primário: Chlamydia trachomatis/genética
Chlamydia trachomatis/isolamento & purificação
Homossexualidade Masculina
Linfogranuloma Venéreo/diagnóstico
Proctite/microbiologia
Reto/microbiologia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Chlamydia trachomatis/classificação
Seres Humanos
Hungria
Linfogranuloma Venéreo/microbiologia
Masculino
Meia-Idade
Dados de Sequência Molecular
Reação em Cadeia da Polimerase
Proctite/diagnóstico
Doenças Retais/diagnóstico
Doenças Retais/microbiologia
Análise de Sequência
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170510
[Lr] Data última revisão:
170510
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170211
[St] Status:MEDLINE


  5 / 2004 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28143418
[Au] Autor:Lee CY; Chen YH; Lu PL
[Ad] Endereço:Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Medical University, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
[Ti] Título:Reactivated cytomegalovirus proctitis in an immunocompetent patient presenting as nosocomial diarrhea: a case report and literature review.
[So] Source:BMC Infect Dis;17(1):113, 2017 Feb 01.
[Is] ISSN:1471-2334
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Reactivated cytomegalovirus (CMV) infection has been known to cause significant morbidity and mortality in immunocompromised patients. However, CMV disease rarely develops in immunocompetent patients, and reported cases often present with a mild, self-limiting course, without severe life-threatening sequelae. While the colon is the most common gastrointestinal site affected by CMV disease in immunocompetent patients, rectal involvement is rarely reported. CMV proctitis can present in two distinct forms, primary and reactivated. However, reactivated CMV proctitis is rarely reported as a causative etiology of nosocomial diarrhea, except in transplant patients. Herein we present a case of reactivated CMV proctitis in an immunocompetent patient, presenting as nosocomial diarrhea. Previously reported cases of reactivated CMV proctitis in immunocompetent patients are also reviewed. CASE PRESENTATION: A 79-year-old female was admitted because of metabolic encephalopathy caused by dehydration and hypernatremia. The patient's consciousness level returned rapidly after fluid supplementation. However, she subsequently presented with abdominal pain and diarrhea on day 8 of admission. Abdominal contrast-enhanced computed tomography on day 10 of admission demonstrated inflammation around the rectum, suggesting proctitis. Colonoscopy on day 16 of admission showed a giant ulcer at the rectum. Pathology of rectal biopsy confirmed CMV infection. The patient recovered without sequelae after 38 days of valganciclovir treatment. Follow-up colonoscopy revealed a healed ulcer over the rectum. Ten cases in the literature, plus our case, with reactivated CMV proctitis in immunocompetent patients were reviewed. We found that most patients were elderly (mean, 72 years) with a high prevalence of diabetes mellitus (54.5%). Cardinal manifestations are often non-specific (diarrhea, hematochezia, tenesmus), and eight (72.7%) developed CMV proctitis following a preceding acute, life-threatening disease, rather than as an initial presentation on admission. These manifestations frequently develop during hospitalization, and are thus often regarded as nosocomial diarrhea. CONCLUSIONS: Clinicians should be aware of the possibility of nosocomial onset of reactivated CMV proctitis in patients hospitalized due to a preceding critical illness, although the benefits of antiviral therapy remain unclear.
[Mh] Termos MeSH primário: Infecção Hospitalar/virologia
Infecções por Citomegalovirus/virologia
Citomegalovirus
Proctite/virologia
Ativação Viral
[Mh] Termos MeSH secundário: Dor Abdominal
Idoso
Biópsia
Colonoscopia
Infecções por Citomegalovirus/imunologia
Diarreia/fisiopatologia
Diarreia/virologia
Feminino
Ganciclovir/análogos & derivados
Ganciclovir/uso terapêutico
Seres Humanos
Imunocompetência
Meia-Idade
Proctite/imunologia
Proctite/fisiopatologia
Reto/patologia
Tomografia Computadorizada por Raios X
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
GCU97FKN3R (valganciclovir); P9G3CKZ4P5 (Ganciclovir)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170629
[Lr] Data última revisão:
170629
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170202
[St] Status:MEDLINE
[do] DOI:10.1186/s12879-017-2218-y


  6 / 2004 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28089625
[Au] Autor:Mallet AL; Bouguen G; Conroy G; Roblin X; Delobel JB; Bretagne JF; Siproudhis L; Peyrin-Biroulet L
[Ad] Endereço:Department of Hepato-Gastroenterology, University Hospital of Pontchaillou, Rennes, France.
[Ti] Título:Azathioprine for refractory ulcerative proctitis: A retrospective multicenter study.
[So] Source:Dig Liver Dis;49(3):280-285, 2017 Mar.
[Is] ISSN:1878-3562
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Efficacy of azathioprine (AZA) in refractory ulcerative proctitis (UP) is unknown. METHODS: All patients treated with AZA for refractory UP in three referral centers between 2002 and 2012 were included. "Treatment success" in the long-term was defined as the absence of colectomy during follow-up, no need for anti-TNF during follow-up, no ongoing systemic steroids use, no adverse event leading to AZA withdrawal, and clinically quiescent disease at last follow-up. RESULTS: Of the 1279 adult patients with ulcerative colitis, 25 patients were treated with AZA for refractory UP (median disease duration 4.9 years). Of these, 4 had no short-term clinical assessment. Of the remaining 21, 4 were primary non responders to AZA, 7 discontinued AZA for adverse events and 10 showed clinical improvement. At the long-term assessment at last follow up after a median of 46 months, 5 patients had treatment success and were still on AZA treatment, the remaining 20 were treatment failures. Of these, 5 discontinued AZA for adverse events and 15 were treated with infliximab (clinical response in 11 patients, primary non-response in one patient, and 3 underwent colectomy). CONCLUSION: AZA may be efficacious in maintaining clinical response in one-fifth of patients with refractory UP in a real-life setting.
[Mh] Termos MeSH primário: Azatioprina/uso terapêutico
Colite Ulcerativa/tratamento farmacológico
Imunossupressores/uso terapêutico
Proctite/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Idoso
Azatioprina/efeitos adversos
Criança
Colectomia
Quimioterapia Combinada
Feminino
Seguimentos
França
Seres Humanos
Imunossupressores/efeitos adversos
Infliximab/uso terapêutico
Masculino
Meia-Idade
Estudos Retrospectivos
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Immunosuppressive Agents); B72HH48FLU (Infliximab); MRK240IY2L (Azathioprine)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170912
[Lr] Data última revisão:
170912
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170117
[St] Status:MEDLINE


  7 / 2004 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27816539
[Au] Autor:Koh V; Choo BA; Lee KM; Tan TH; Low JH; Ng SY; Ilancheran A; Shen L; Tang J
[Ad] Endereço:Department of Radiation Oncology, National University Cancer Institute Singapore, Singapore. Electronic address: vicky_koh@nuhs.edu.sg.
[Ti] Título:Feasibility study of toxicity outcomes using GEC-ESTRO contouring guidelines on CT based instead of MRI-based planning in locally advanced cervical cancer patients.
[So] Source:Brachytherapy;16(1):126-132, 2017 Jan - Feb.
[Is] ISSN:1873-1449
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To report late rectal and bladder toxicity outcomes of a CT-based image-guided brachytherapy (IGBT) technique for treatment of cervical cancer. METHODS AND MATERIALS: Between 2008 and 2014, 95 women with International Federation of Gynecology and Obstetrics stage IB to IVA cervical carcinoma treated with definitive concurrent cisplatin-based chemotherapy and external beam radiation therapy 50.4 Gy in 28 fractions followed by planned prescription dose of 7 Gy × 4 fractions of high-dose-rate IGBT was retrospectively reviewed. At each implantation, all patients had a urinary catheter in situ and received bowel enema before undergoing planning CT simulation. A high-risk clinical target volume (HRCTV) as per GEC-ESTRO guidelines and the entire cervix, rectum, and bladder was contoured on the simulation CT according to Radiation Therapy Oncology Group Gynaecology Contouring Atlas. Reported doses to HRCTV and organs at risk were recorded. Toxicities were recorded using National Cancer Institute Common Terminology Criteria for Adverse Events version 3. RESULTS: The median followup time was 29 months. The mean HRCTV equivalent dose in 2 Gy fractions (EQD2) of external beam radiation therapy combined with brachytherapy was 80 Gy (standard deviation [SD], 11), and the rectal doses to 2 cm (D2cc) EQD2 and bladder D2cc EQD2 were 74 Gy (SD, 6) and 79 Gy (SD, 15), respectively. Twenty-two patients (23%) had grade 2 proctitis and 10 patients (11%) had grade 3 proctitis. Four patients (4%) had grade 2 cystitis and two patients (2%) had grade 3 cystitis. No patients had ≥ grade 4 toxicity. CONCLUSIONS: Despite CT-based brachytherapy planning, reported organ at risk toxicity was still significant compared with reported MRI-based planning series. Coimplementation of interstitial IGBT using the European Study on MRI-guided Brachytherapy in Locally Advanced Cervical Cancer (EMBRACE) protocol or using intensity-modulated radiation therapy during the external beam phase treatment might help to limit these late toxicities.
[Mh] Termos MeSH primário: Adenocarcinoma/terapia
Braquiterapia/métodos
Carcinoma de Células Escamosas/terapia
Cistite/epidemiologia
Proctite/epidemiologia
Lesões por Radiação/epidemiologia
Neoplasias do Colo do Útero/terapia
[Mh] Termos MeSH secundário: Adenocarcinoma/diagnóstico por imagem
Adenocarcinoma/patologia
Adulto
Idoso
Antineoplásicos/uso terapêutico
Braquiterapia/efeitos adversos
Carcinoma de Células Escamosas/diagnóstico por imagem
Carcinoma de Células Escamosas/patologia
Quimiorradioterapia/métodos
Cisplatino/uso terapêutico
Colo Sigmoide/diagnóstico por imagem
Cistite/etiologia
Estudos de Viabilidade
Feminino
Seres Humanos
Meia-Idade
Órgãos em Risco
Proctite/etiologia
Lesões por Radiação/etiologia
Dosagem Radioterapêutica
Planejamento da Radioterapia Assistida por Computador/métodos
Radioterapia de Intensidade Modulada/métodos
Reto/diagnóstico por imagem
Estudos Retrospectivos
Tomografia Computadorizada por Raios X/métodos
Bexiga Urinária/diagnóstico por imagem
Neoplasias do Colo do Útero/diagnóstico por imagem
Neoplasias do Colo do Útero/patologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); Q20Q21Q62J (Cisplatin)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170726
[Lr] Data última revisão:
170726
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161107
[St] Status:MEDLINE


  8 / 2004 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27663931
[Au] Autor:Weiner J; Schwartz D; Martinez M; Safdieh J; Aytaman A; Schreiber D
[Ad] Endereço:Department of Radiation Oncology, Veterans Affairs New York Harbor Healthcare System, Brooklyn, New York; Department of Radiation Oncology, State University of New York Downstate Medical Center, Brooklyn, New York. Electronic address: joseph.p.weiner@gmail.com.
[Ti] Título:Long-term results on the efficacy of argon plasma coagulation for patients with chronic radiation proctitis after conventionally fractionated, dose-escalated radiation therapy for prostate cancer.
[So] Source:Pract Radiat Oncol;7(1):e35-e42, 2017 Jan - Feb.
[Is] ISSN:1879-8519
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: This study was designed to assess the efficacy and outcomes of argon plasma coagulation (APC) in the management of chronic radiation proctitis after conventionally fractionated, dose-escalated radiation therapy (≥7560 cGy). METHODS AND MATERIALS: We retrospectively reviewed the charts on all patients treated with external beam radiation therapy (minimum dose, 7560 cGy) for histologically confirmed prostate cancer at our institution from 2003 to 2011. Five hundred patients met these criteria; of these, 35 patients (7.0%) developed radiation proctitis necessitating intervention with APC. Indications for APC treatment were either the need for blood transfusions resulting from proctitis-related anemia or refractory bleeding despite medical management. RESULTS: The median follow-up from the completion of radiation treatment was 78 months (range, 19-129) and the median follow up from the most recent APC treatment was 56 months (range, 3-112). Fifteen men (42.9%) needed blood transfusions because of proctitis-related anemia. For 19 patients (54.3%), bleeding was controlled after 1 or 2 treatments. Eventual bleeding control was obtained in 30 patients (85.7%). The median number of sessions per patient was 2 (range, 1-13). Post-APC ulceration was noted in 8 cases (22.9%). Two patients (5.7%) developed colovesicular fistulas, with 1 patient dying from this complication. A short interval between treatments (≤35 days) was associated with an increased risk of ulcer or fistula formation. CONCLUSIONS: APC is an effective treatment for patients with medically refractive radiation proctitis after dose-escalated radiation therapy, frequently controlling bleeding after only one or two sessions. However, rectal ulceration is a common complication, along with a small risk of life-threatening toxicity.
[Mh] Termos MeSH primário: Coagulação com Plasma de Argônio
Fracionamento de Dose
Proctite/terapia
Neoplasias da Próstata/radioterapia
Lesões por Radiação/terapia
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Doença Crônica
Seres Humanos
Masculino
Meia-Idade
Estudos Retrospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170419
[Lr] Data última revisão:
170419
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160925
[St] Status:MEDLINE


  9 / 2004 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27600606
[Au] Autor:Cordoba A; Escande A; Leroy T; Mirabel X; Coche-Dequéant B; Lartigau E
[Ad] Endereço:Academic Radiation Oncology Department, Oscar Lambret Comprehensive Cancer Center, SIRIC ONCOLille and University Lille 2, Lille, France. Electronic address: a-cordoba@o-lambret.fr.
[Ti] Título:Low-dose-rate interstitial brachytherapy boost for the treatment of anal canal cancers.
[So] Source:Brachytherapy;16(1):230-235, 2017 Jan - Feb.
[Is] ISSN:1873-1449
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Evaluate the efficacy and tolerance of interstitial brachytherapy (IBT) after external beam radiotherapy (EBRT) or radio chemotherapy (RCT) for the treatment of anal canal cancers (ACC). METHODS AND MATERIALS: From 01, 1990 to 01, 2013, 103 patients (p) with ACC were treated with IBT after EBRT or RCT at our institution. Tumor node metastasis stage included Tis (1 p), T1 (18 p), T2 (46 p), T3 (33 p), and T4 (5 p). There was a lymph node involvement in 19 p. Ninety-nine patients presented with squamous cell carcinoma (95.5%) and seven with adenocarcinoma (4.5%). The median EBRT dose was 45 Gy (18-65 Gy). Thirty-nine patients (37.86%) received concomitant RCT. IBT was performed 0.9 months (0-4.38) after RCT or EBRT. The median IBT dose was 17.2 Gy (10-30 Gy). RESULTS: Within 4.8 years of followup, 15 p (14.6%) had an abdominoperineal amputation with definitive colostomy (11 p had locoregional failure, and 4 p had anal incontinence). Late toxicity was presented in 40 p (38.8%). Overall survival rates of 99% at 1 year, 89.4% at 3 years, and 85.7% at 5 years, and 1-year, 3-year, and 5-year local control rates of 97.9%, 95.4%, and 89.1%, respectively. The 1-year, 3-year, and 5-year colostomy-free rates were 98.9%, 94.0%, and 86.4%, respectively. No factors in the multivariate analysis were associated with the overall survival or any failure type. CONCLUSIONS: IBT boost provides excellent local control with low colostomy rates and a late toxicity profile in ACC treatment.
[Mh] Termos MeSH primário: Adenocarcinoma/radioterapia
Neoplasias do Ânus/radioterapia
Braquiterapia/métodos
Carcinoma de Células Escamosas/radioterapia
[Mh] Termos MeSH secundário: Adenocarcinoma/patologia
Adulto
Idoso
Idoso de 80 Anos ou mais
Canal Anal
Neoplasias do Ânus/patologia
Braquiterapia/efeitos adversos
Carcinoma de Células Escamosas/patologia
Quimiorradioterapia
Colostomia/utilização
Terapia Combinada
Cistite/epidemiologia
Cistite/etiologia
Procedimentos Cirúrgicos do Sistema Digestório/utilização
Intervalo Livre de Doença
Dispareunia/epidemiologia
Dispareunia/etiologia
Feminino
Seguimentos
Hemorragia Gastrointestinal/epidemiologia
Hemorragia Gastrointestinal/etiologia
Seres Humanos
Masculino
Meia-Idade
Análise Multivariada
Recidiva Local de Neoplasia/epidemiologia
Estadiamento de Neoplasias
Proctite/epidemiologia
Proctite/etiologia
Lesões por Radiação/epidemiologia
Lesões por Radiação/etiologia
Radioterapia/efeitos adversos
Dosagem Radioterapêutica
Estudos Retrospectivos
Taxa de Sobrevida
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170726
[Lr] Data última revisão:
170726
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160908
[St] Status:MEDLINE


  10 / 2004 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27527929
[Au] Autor:Siow SL; Mahendran HA; Seo CJ
[Ad] Endereço:Department of Surgery, Sarawak General Hospital, Kuching, Sarawak, Malaysia. szeli18@yahoo.com.
[Ti] Título:Complication and remission rates after endoscopic argon plasma coagulation in the treatment of haemorrhagic radiation proctitis.
[So] Source:Int J Colorectal Dis;32(1):131-134, 2017 Jan.
[Is] ISSN:1432-1262
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:PURPOSE: The management of haemorrhagic radiation proctitis is challenging because of the necessity for repeated intervention. The efficacy of argon plasma coagulation has been described before but the optimum treatment strategy remains debatable. This is a review of our experience over a decade treating patients with haemorrhagic radiation proctitis and their follow-up. METHODS: This is a retrospective review of consecutive patients who underwent argon plasma coagulation for haemorrhagic radiation proctitis between January 2003 and December 2013. The patients were followed up using a prospectively maintained database. RESULTS: Ninety-one patients were included with a mean follow-up of 13.1 months. Majoity (n = 85, 93.4 %) of the patients were female. Mean age at the time of treatment was 58.2 (range 23-87) years old. Majority of the patients (n = 73, 80.2 %) received radiotherapy for gynaecological malignancies followed by colorectal (n = 13, 14.3 %) and urological (n = 5, 5.5 %) malignancies. Mean interval between radiation and proctitis was 13.8 (range 3-40) months. Seventy-nine percent of patients were successfully treated after 1-2 sessions. Seventeen (18.7 %) patients experienced self-limiting early complications, and three (3.3 %) had late complications of rectal stenosis which was managed conservatively. Severity of bleeding during the initial presentation is an independent factor that predicts the number of sessions required for successful haemostasis (p = 0.002). CONCLUSIONS: Argon plasma coagulation is a reasonable treatment option in patients with haemorrhagic radiation proctitis with good safety profile. Our study suggests that the number of APC sessions required to arrest bleeding correlates with the severity of bleeding on initial presentation.
[Mh] Termos MeSH primário: Coagulação com Plasma de Argônio/efeitos adversos
Endoscopia/efeitos adversos
Hemorragia Gastrointestinal/complicações
Hemorragia Gastrointestinal/terapia
Proctite/complicações
Proctite/terapia
Lesões por Radiação/complicações
Lesões por Radiação/terapia
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Feminino
Seres Humanos
Masculino
Meia-Idade
Indução de Remissão
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170926
[Lr] Data última revisão:
170926
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160817
[St] Status:MEDLINE
[do] DOI:10.1007/s00384-016-2635-1



página 1 de 201 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde